{"disease":{"id":"persistent","name":"persistent"},"drugs":{"marketed":[{"drug_id":"eltrombopag","indication_name":"Persistent or Chronic ITP","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Promacta","generic_name":"ELTROMBOPAG","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist","quality_score":80,"revenue":"569","mechanism":"Promacta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."},{"drug_id":"methadone","indication_name":"Severe and Persistent Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methadone Hydrochloride","generic_name":"METHADONE","company_name":"Specgx Llc","drug_phase":"marketed","molecular_target":"mu-opioid receptors, NMDA receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Methadone is a synthetic opioid that acts as a mu-agonist, providing analgesia and aiding in opioid addiction management."},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"rilzabrutinib","indication_name":"persistent or chronic immune thrombocytopenia (ITP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wayrilz","generic_name":"RILZABRUTINIB","company_name":"Genzyme Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":48,"revenue":null,"mechanism":"Wayrilz works by blocking a specific enzyme that helps platelet-destroying immune cells function."},{"drug_id":"nitric-oxide","indication_name":"Persistent pulmonary hypertension of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inomax","generic_name":"NITRIC OXIDE","company_name":"Vero Biotech Inc","drug_phase":"marketed","molecular_target":"Soluble guanylate cyclase","drug_class":"Standardized Chemical Allergen [EPC]","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"erythromycin","indication_name":"Recurrent Persistent Urethritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"E-Mycin","generic_name":"erythromycin","company_name":"Generic (originally Abbott/Lilly)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1","drug_class":"Macrolide [EPC]","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"nitrogen-nf","indication_name":"Persistent pulmonary hypertension of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NITROGEN, NF","generic_name":"NITROGEN, NF","company_name":"UNIVERSAL INDUSTRIAL GASES, INC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"erythrocin","indication_name":"Recurrent Persistent Urethritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzamycin","generic_name":"Erythromycin Lactobionate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Macrolide","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bevacizumab-maly","indication_name":"Persistent, Recurrent, or Metastatic Cervical Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"tolazoline","indication_name":"Persistent pulmonary hypertension of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vasodil","generic_name":"TOLAZOLINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"tolazoline","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":46,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04088071","title":"Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Heart Rhythm Clinical and Research Solutions, LLC","has_results":false},{"nct_id":"NCT05334927","title":"China HeadAche DIsorders RegiStry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT01735006","title":"Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":7372,"lead_sponsor_name":"Xiamen University","has_results":false},{"nct_id":"NCT06024161","title":"Weight Change and the Risk of Chronic Pain Following Hip and Knee Arthroplasties","phase":"","overall_status":"UNKNOWN","enrollment_count":6400,"lead_sponsor_name":"Bispebjerg Hospital","has_results":false},{"nct_id":"NCT05006456","title":"Real-world Experience of Catheter Ablation Using Novel Ablation Technologies for the Treatment of Atrial Fibrillation","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT05900791","title":"Persistent Pain After Knee Replacement","phase":"","overall_status":"COMPLETED","enrollment_count":3710,"lead_sponsor_name":"University Hospital Bispebjerg and Frederiksberg","has_results":false},{"nct_id":"NCT04916678","title":"Persistent PostConcussion-Like Symptoms and Post Traumatic Stress Disorder in Patients Presenting at the Emergency Room.","phase":"NA","overall_status":"COMPLETED","enrollment_count":2897,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT05845177","title":"Persistent Pain After Hip Replacement","phase":"","overall_status":"COMPLETED","enrollment_count":2777,"lead_sponsor_name":"University Hospital Bispebjerg and Frederiksberg","has_results":false},{"nct_id":"NCT06243666","title":"Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2188,"lead_sponsor_name":"Xiamen University","has_results":false},{"nct_id":"NCT05441059","title":"Use of Nucala in Severe Asthma","phase":"","overall_status":"COMPLETED","enrollment_count":2100,"lead_sponsor_name":"Frisius Medisch Centrum","has_results":false},{"nct_id":"NCT06836999","title":"Deep Sedation in Catheter Ablation of Atrial Fibrillation","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1334,"lead_sponsor_name":"The First Affiliated Hospital of Dalian Medical University","has_results":false},{"nct_id":"NCT04489004","title":"The Chinese Registration Study of Driver Ablation of Persistent Atrial Fibrillation.","phase":"NA","overall_status":"COMPLETED","enrollment_count":1298,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT05773170","title":"Efficacy and Safety Evaluation of Refralon®, Concentrate for Solution for Intravenous Injection in Patients With Paroxysmal and Persistent Atrial Fibrillation and Flutter","phase":"","overall_status":"COMPLETED","enrollment_count":1147,"lead_sponsor_name":"R-Pharm","has_results":false},{"nct_id":"NCT05749107","title":"In-depth Characterization of Atriogenic Secondary Tricuspid Regurgitation Due to Atrial Fibrillation","phase":"","overall_status":"UNKNOWN","enrollment_count":1050,"lead_sponsor_name":"Istituto Auxologico Italiano","has_results":false},{"nct_id":"NCT02562508","title":"A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":979,"lead_sponsor_name":"Jun Zhang","has_results":false},{"nct_id":"NCT03206255","title":"Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls","phase":"","overall_status":"COMPLETED","enrollment_count":940,"lead_sponsor_name":"Jun Zhang","has_results":false},{"nct_id":"NCT05247502","title":"Impact of the Characteristics of Acute Renal Failure in Intensive Care on the Long-term Renal Prognosis: Prospective Multicenter Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":860,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT07508618","title":"Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":846,"lead_sponsor_name":"Sir Run Run Shaw Hospital","has_results":false},{"nct_id":"NCT05984719","title":"New Daily Persistent Headache Survey","phase":"","overall_status":"COMPLETED","enrollment_count":803,"lead_sponsor_name":"The University of Texas Health Science Center, Houston","has_results":false},{"nct_id":"NCT06433336","title":"Effect of Blood Pressure on Cardiovascular Outcomes and Recurrence After Catheter Ablation in Patients With Atrial Fibrillation","phase":"","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Lanzhou University Second Hospital","has_results":false},{"nct_id":"NCT02513160","title":"Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":713,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT07089914","title":"Health Surveillance at University of Applied Science Hamburg (HAW)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":700,"lead_sponsor_name":"Jacobs University Bremen gGmbH","has_results":false},{"nct_id":"NCT06791629","title":"Pulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":700,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT05443594","title":"A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation","phase":"NA","overall_status":"COMPLETED","enrollment_count":669,"lead_sponsor_name":"Boston Scientific Corporation","has_results":true},{"nct_id":"NCT07106970","title":"PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II)","phase":"NA","overall_status":"RECRUITING","enrollment_count":640,"lead_sponsor_name":"Boston Scientific Corporation","has_results":false},{"nct_id":"NCT07096219","title":"Catheter Ablation for Functional Mitral Regurgitation in Persistent Atrial Fibrillation: Development and Validation of a Predictive Model-A Multicenter Prospective Cohort Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":556,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05426148","title":"Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":540,"lead_sponsor_name":"Xiamen Innovax Biotech Co., Ltd","has_results":false},{"nct_id":"NCT04480242","title":"Asthma Research in Children and Adolescents","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":525,"lead_sponsor_name":"Parc de Salut Mar","has_results":false},{"nct_id":"NCT04379180","title":"Population Pharmacokinetics and Dosage Individualization of Oral Pulmonary Vasodilators in PPHN","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Shandong University","has_results":false},{"nct_id":"NCT04342312","title":"Intensive Molecular and Electropathological Characterization of Patients Undergoing Atrial Fibrillation Ablation","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Maastricht University","has_results":false},{"nct_id":"NCT04497376","title":"Comparison Between Upgraded '2C3L' vs. PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation","phase":"NA","overall_status":"COMPLETED","enrollment_count":498,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT06096337","title":"Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":484,"lead_sponsor_name":"Boston Scientific Corporation","has_results":false},{"nct_id":"NCT05776797","title":"AV Junction Ablation or Optimal Medical Treatment in PatiEnts With Cardiac Resynchronization Therapy and Permanent Atrial Fibrillation","phase":"NA","overall_status":"RECRUITING","enrollment_count":480,"lead_sponsor_name":"University Hospital Ostrava","has_results":false},{"nct_id":"NCT06247852","title":"Persistent Pain After Cesarean Delivery - A Danish Multicenter Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":477,"lead_sponsor_name":"Nordsjaellands Hospital","has_results":false},{"nct_id":"NCT05264831","title":"Pulmonary Vein Isolation Alone or in Combination With Substrate Modulation After Electric Cardioversion Failure","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Elsan","has_results":false},{"nct_id":"NCT06671197","title":"Study on the Ablation of Persistent Atrial Fibrillation Using Pulsed Electric Fields Under Different Surgical Procedures","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":436,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05204212","title":"Left Atrial Appendage Closure in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic KIDNEY Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":430,"lead_sponsor_name":"Prof. Dr. med. Ingo Eitel","has_results":false},{"nct_id":"NCT05798819","title":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":424,"lead_sponsor_name":"Guangzhou Gloria Biosciences Co., Ltd.","has_results":false},{"nct_id":"NCT03881657","title":"Reverse Colocated Integrated Care Intervention Among Persons With Severe Persistent Mental Illness at US-Mexico Border","phase":"NA","overall_status":"COMPLETED","enrollment_count":416,"lead_sponsor_name":"Health Resources in Action, Inc.","has_results":false},{"nct_id":"NCT07298473","title":"Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Medtronic Cardiac Ablation Solutions","has_results":false},{"nct_id":"NCT05407610","title":"Comparison of Conventional and Cooled Radiofrequency of the Genicular Nerves in Patients With Chronic Knee Pain","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Ziekenhuis Oost-Limburg","has_results":false},{"nct_id":"NCT06223789","title":"VOLT-AF IDE Clinical Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":392,"lead_sponsor_name":"Abbott Medical Devices","has_results":false},{"nct_id":"NCT07122336","title":"Optimized Ablation of the Posterior Wall in Persistent Atrial Fibrillation","phase":"NA","overall_status":"RECRUITING","enrollment_count":384,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT06633523","title":"Optimized Posterior Left Atrial Wall Ablation Strategy for PeAF","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":384,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT03733392","title":"Advisor HD Grid Observational Study","phase":"","overall_status":"COMPLETED","enrollment_count":379,"lead_sponsor_name":"Abbott Medical Devices","has_results":true},{"nct_id":"NCT03643224","title":"DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation","phase":"NA","overall_status":"COMPLETED","enrollment_count":376,"lead_sponsor_name":"Medtronic Cardiac Ablation Solutions","has_results":true},{"nct_id":"NCT06899308","title":"Health Surveillance at Constructor University Bremen (CUB) and Among HAW-Hamburg Employees","phase":"","overall_status":"RECRUITING","enrollment_count":363,"lead_sponsor_name":"Jacobs University Bremen gGmbH","has_results":false},{"nct_id":"NCT06792656","title":"Measuring the Effectiveness of Forest Therapy to Alleviate Stress Among International Students","phase":"NA","overall_status":"COMPLETED","enrollment_count":360,"lead_sponsor_name":"International Nature and Forest Therapy Alliance","has_results":false},{"nct_id":"NCT04542785","title":"Lenient Rate Control Versus Strict Rate Control for Atrial Fibrillation. The Danish Atrial Fibrillation Randomised Clinical Trial","phase":"NA","overall_status":"UNKNOWN","enrollment_count":350,"lead_sponsor_name":"Holbaek Sygehus","has_results":false},{"nct_id":"NCT05030272","title":"Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings","phase":"NA","overall_status":"COMPLETED","enrollment_count":343,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}